255 related articles for article (PubMed ID: 34374445)
1. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
[TBL] [Abstract][Full Text] [Related]
3. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Munshi PN; Vesole D; Jurczyszyn A; Zaucha JM; St Martin A; Davila O; Agrawal V; Badawy SM; Battiwalla M; Chhabra S; Copelan E; Kharfan-Dabaja MA; Farhadfar N; Ganguly S; Hashmi S; Krem MM; Lazarus HM; Malek E; Meehan K; Murthy HS; Nishihori T; Olin RL; Olsson RF; Schriber J; Seo S; Shah G; Solh M; Tay J; Kumar S; Qazilbash MH; Shah N; Hari PN; D'Souza A
Cancer; 2020 Dec; 126(23):5077-5087. PubMed ID: 32965680
[TBL] [Abstract][Full Text] [Related]
4. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.
Dhakal B; Nelson A; Guru Murthy GS; Fraser R; Eastwood D; Hamadani M; Pasquini M; D'Souza A; Hari P
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):165-172. PubMed ID: 28159578
[TBL] [Abstract][Full Text] [Related]
5. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Schriber JR; Hari PN; Ahn KW; Fei M; Costa LJ; Kharfan-Dabaja MA; Angel-Diaz M; Gale RP; Ganguly S; Girnius SK; Hashmi S; Pawarode A; Vesole DH; Wiernik PH; Wirk BM; Marks DI; Nishihori T; Olsson RF; Usmani SZ; Mark TM; Nieto YL; D'Souza A
Cancer; 2017 Aug; 123(16):3141-3149. PubMed ID: 28472539
[TBL] [Abstract][Full Text] [Related]
6. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401
[TBL] [Abstract][Full Text] [Related]
8. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Badar T; Hari P; Dávila O; Fraser R; Wirk B; Dhakal B; Freytes CO; Rodriguez Valdes C; Lee C; Vesole DH; Malek E; Hildebrandt GC; Landau H; Murthy HS; Lazarus HM; Berdeja JG; Meehan KR; Solh M; Diaz MA; Kharfan-Dabaja MA; Callander NS; Farhadfar N; Bashir Q; Kamble RT; Vij R; Munker R; Kyle RA; Chhabra S; Hashmi S; Ganguly S; Jagannath S; Nishihori T; Nieto Y; Kumar S; Shah N; D'Souza A
Cancer; 2021 Jan; 127(1):82-92. PubMed ID: 32966625
[TBL] [Abstract][Full Text] [Related]
9. Melphalan 140 mg/m
Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
[TBL] [Abstract][Full Text] [Related]
10. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
Costa LJ; Huang JX; Hari PN
Biol Blood Marrow Transplant; 2015 Apr; 21(4):701-6. PubMed ID: 25555447
[TBL] [Abstract][Full Text] [Related]
11. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
Hari PN; Majhail NS; Zhang MJ; Hassebroek A; Siddiqui F; Ballen K; Bashey A; Bird J; Freytes CO; Gibson J; Hale G; Holmberg L; Kamble R; Kyle RA; Lazarus HM; LeMaistre CF; Loberiza F; Maiolino A; McCarthy PL; Milone G; Omondi N; Reece DE; Seftel M; Trigg M; Vesole D; Weiss B; Wiernik P; Lee SJ; Rizzo JD; Mehta P
Biol Blood Marrow Transplant; 2010 Mar; 16(3):395-402. PubMed ID: 19922808
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
14. Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review.
Lupak O; Xiaoxia H; Xie P; Thanikachalam K; Jabbour-Aida H; Farhan S; Emole J
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e680-e685. PubMed ID: 34148850
[TBL] [Abstract][Full Text] [Related]
15. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.
Kumar SK; Dispenzieri A; Fraser R; Mingwei F; Akpek G; Cornell R; Kharfan-Dabaja M; Freytes C; Hashmi S; Hildebrandt G; Holmberg L; Kyle R; Lazarus H; Lee C; Mikhael J; Nishihori T; Tay J; Usmani S; Vesole D; Vij R; Wirk B; Krishnan A; Gasparetto C; Mark T; Nieto Y; Hari P; D'Souza A
Leukemia; 2018 Apr; 32(4):986-995. PubMed ID: 29263438
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
17. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
Chen AI; Negrin RS; McMillan A; Shizuru JA; Johnston LJ; Lowsky R; Miklos DB; Arai S; Weng WK; Laport GG; Stockerl-Goldstein K
Bone Marrow Transplant; 2012 Apr; 47(4):516-21. PubMed ID: 21602899
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Mahindra A; Hari P; Fraser R; Fei M; Huang J; Berdeja J; Callander N; Costa L; Diaz MA; Freytes C; Gale RP; Girnius S; Holmberg L; Kharfan-Dabaja M; Kumar S; Kyle R; Lazarus H; Lee C; Maiolino A; Moreb J; Nishihori T; Pawarode A; Saad A; Savani BN; Schriber J; William B; Wirk BM; Krishnan A; Nieto Y; D'Souza A
Bone Marrow Transplant; 2017 Dec; 52(12):1616-1622. PubMed ID: 28920949
[TBL] [Abstract][Full Text] [Related]
19. Older patients with myeloma derive similar benefit from autologous transplantation.
Sharma M; Zhang MJ; Zhong X; Abidi MH; Akpek G; Bacher U; Callander NS; Dispenzieri A; Freytes CO; Fung HC; Gale RP; Gasparetto C; Gibson J; Holmberg LA; Kindwall-Keller TL; Klumpp TR; Krishnan AY; Landau HJ; Lazarus HM; Lonial S; Maiolino A; Marks DI; Mehta P; Mikhael Med JR; Nishihori T; Olsson R; Ramanathan M; Roy V; Savani BN; Schouten HC; Scott E; Tay J; To LB; Vesole DH; Vogl DT; Hari P
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1796-803. PubMed ID: 25046833
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
